Abstract: The present invention is directed to novel processes for the functionalization (derivatization) of carbon nanotubes and, as an extension, to fullerenes and other carbon surfaces. Generally, such processes involve reductive pathways. In some embodiments, carbon nanotubes are reacted with alkali metal and organic halides in anhydrous liquid ammonia. In other embodiments, polymers are grown from carbon nanotube sidewalls by reacting carbon nanotubes with alkali metal and monomer species in anhydrous liquid ammonia.

Abstract: A process for producing a filmy graphite includes the steps of forming a polyimide film having a birefringence of 0.12 or more and heat-treating the polyimide film at 2,400° C. or higher.

Abstract: The present disclosure provides systems and methods for crystal growth of cadmium zinc tellurium (CZT) and cadmium tellurium (CdTe) crystals with an inverted growth reactor chamber. The inverted growth reactor chamber enables growth of single, large, high purity CZT and CdTe crystals that can be used, for example, in X-ray and gamma detection, substrates for infrared detectors, or the like. The inverted growth reactor chamber enables reductions in the presence of Te inclusions, which are recognized as an important limiting factor in using CZT or CdTe as radiation detectors. The inverted growth reactor chamber can be utilized with existing crystal growth techniques such as the Bridgman crystal growth mechanism and the like. In an exemplary embodiment, the inverted growth reactor chamber is a U-shaped ampoule.

Abstract: There is provided a titanium oxide powder having excellent ultraviolet-protecting ability, usability and transparency, and a method of manufacturing the same. The titanium oxide powder provided is a porous titanium oxide powder that is formed from titanium oxide primary particles agglomerated together, has a mean particle diameter of 0.01 to 100 ?m, and has a specific surface area of 250 to 500 m2/g. The porous titanium oxide powder can be obtained by subjecting a titanium salt solution to hydrolysis by heating under the presence of an aliphatic alcohol and/or a substance having a carboxyl group or a carbonyl group, and then further carrying out heating treatment with an acid. The titanium oxide primary particles preferably have a mean particle diameter of 1 to 50 nm, and the powder preferably has an approximately spherical shape with the ratio of the minor axis to the major axis being at least 0.75.

Abstract: The present invention provides a method for producing an ?-alumina particle. The method for producing an ?-alumina particle comprises steps of: (1) placing a powdery mixture containing an aluminum salt and a seed crystal under a circumstance at not less than pyrolysis temperature of the aluminum salt, and (2) calcining the resultant.

Abstract: Methods for producing hydrogen via the water-gas shift reaction utilizing a palladium-zinc on alumina catalyst are described.

Abstract: A MFI-structured molecular sieve containing phosphorus and metal components has a formula expressed in anhydrous form and on the basis of oxide weight, as follows: (0˜0.3) Na2O (0.5˜5.5) Al2O3 (1.3˜10) P2O5 (0.7˜15) M1xOy (0.01˜5) M2mOn (70˜97) SiO2, wherein M1 is one of transition metals selected from the group consisting of Fe, Co and Ni, and M2 is any one of metals selected from the group consisting of Zn, Mn, Ga and Sn. Preparation processes and uses of the instant molecular sieve are also provided. The molecular sieve has an excellent performance for increasing the yield of lower olefins and increasing the aromatics content in gasoline, and can be used as a shape-selective active component for the catalytic cracking catalyst of petroleum hydrocarbons or its additives.

Abstract: The invention relates to a physiologically acceptable composition, especially a cosmetic composition, containing: at least one structuring agent selected from the group consisting of a polyorganosiloxane-containing polymer, a non-silicone-polyamide copolymer, a wax, and mixtures thereof; (b) a hydrocarbyl-functional silicone polymer; (c) optionally, at least one silicone film former; (d) optionally, at least one volatile oil; and (e) optionally, at least one pigment.

Abstract: The solid hair wax product for treating or setting up a human hair-do or hair style contains at least one silicone-free wax, at least one hydrophobic oil that is liquid at 25° C. and at least one silicone wax with a melting point in a range of from 20 to 45° C. Preferably the silicone-free wax is a hydrocarbon wax, the hydrophobic oil is a silicone oil and the silicone wax is an alkylmethyl-dimethyl-siloxane.

Abstract: The invention relates to preservative systems which are particularly suitable in cosmetic and dermatological preparations. The preservative system which comprises a cationic surfactant, derived from the condensation of fatty acids and esterified dibasic amino acids, having the formula (I) where: X? is Br?, Cl?, or HSO4 R1: is a straight alkyl chain from an acid or saturated fatty hydroxy acid from 8 to 14 atoms of carbon bonded to the ?-amino acid group through amidic bond. R2: is a straight or branched alkyl chain from 1 to 18 carbon atoms or aromatic. R3: is: (II) where n can be from 0 to 4, is combined with at least one other ionic or non-ionic preservative agent, whereby the combination displays a synergetic activity. A preservative system, wherein the cationic surfactant preservative derived from the condensation of fatty acids and esterified dibasic amino acid is LAE is particularly preferred.

Abstract: The present invention discloses peptides isolated from the extracellular domain of OX40 Ligand (OX40L) capable of binding OX40 Receptor (OX40R) and inhibiting OX40R-OX40L interaction. Such peptides, fusion proteins comprising them, as well as peptides and other molecules designed on their sequences, can be used as OX40R binding agents competing with natural OX40L for blocking OX40R-mediated cell signaling in the prophylaxis and/or treatment of diseases related to activated T cells.

Abstract: A protein which induces the IFN-? production by immunocompetent cells and has a molecular weight of 19,000±5,000 daltons on SDS-PAGE or gel filtration method and a pI of 4.8±1.0 on chromatofocusing. The protein is isolated from mouse liver and can be purified by a monoclonal antibody specific to it. The monoclonal antibody can be also used for assaying the protein.

Abstract: Antimicrobial agents that can serve as replacements to conventional pharmaceutical antibiotics are disclosed. The antimicrobial agents comprise conjugatively transmissible plasmids that kill targeted pathogenic bacteria, but are not harmful to donor bacteria. Two types of lethal transmissible plasmids are disclosed. One type kills recipient bacteria by unchecked (“runaway”) replication in the recipient cells and is prevented from occuring in donor cells. Another type kills recipient bacteria by expressing a gene that produces a product detrimental or lethal to recipient bacterial cells, that gene being prevented from expression in donor cells.

Abstract: The invention is related to intracellularly induced bacterial DNA promoters and vaccines against Bacillus anthracis.

Abstract: The present invention provides a composition for treating a bacterial biofilm, comprising a first bacteriophage that is capable of infecting a bacterium within said biofilm, and a first polysaccharide lyase enzyme that is capable of degrading a polysaccharide within said biofilm. The composition preferably further comprises a pharmaceutically-acceptable antimicrobial agent, and may also include a DNase. Also provided are modified bacteriophages, methods of creating modified bacteriophages, use of said compositions and bacteriophage for treating biofilms, and methods for treating biofilms using the bacteriophages and compositions of the invention.

Abstract: A protocol of activating and administering human blood cells so that bone marrow histology and/or blood cell counts of patients suffering from a plastic anemia approach normal. The protocol includes culturing the blood cells in the presence of a cytokine and an ionophore. It is emphasized that this abstract is provided to comply with the rules requiring an abstract that will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims. 37 C.F.R. §1.72(b).

Abstract: Compositions and methods for increasing bone density using antibodies directed to a novel class or family of TGF-? binding proteins are provided. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases associated with a loss of bone density, for example osteoporosis.

Abstract: Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in research, diagnostic and therapeutic applications.

Abstract: Protein formulations and methods for reducing the viscosity of a protein formulation are provided. The method for reducing the viscosity of a protein formulation comprises adding a viscosity reducing agent, such as calcium chloride or magnesium chloride to the protein formulation.

Abstract: The present invention discloses dye-sulfenate derivatives and their bioconjugates for dual phototherapy of tumors and other lesions. The compounds of the present invention may contain either a mixture of Type 1 and Type 2 agents or a single entity that integrates both units in the same molecules. The compounds are designed to produce both Type 1 and Type 2 phototherapeutic effect at once using dual wavelength light source that will produce singlet oxygen and free radicals at the lesion of interest.

Abstract: Novel polypeptides that are splice variants of c-Met, the receptor for hepatocyte growth factor and polynucleotides encoding same are provided. Methods and pharmaceutical compositions which can be used to treat various disorders such as cancer, immunological-related, blood-related and skin-related disorders using the polypeptides and polynucleotides of the present invention, are also provided.

Abstract: Peptides of influenza virus hemagglutinin protein and Plasmodium falciparum malaria antigen, antibodies specific for the peptides, influenza vaccines, malaria vaccines and methods of stimulating the immune response of a subject to produce antibodies to influenza virus or malaria are disclosed. Also disclosed are methods for formulating vaccines for influenza virus.

Abstract: The present invention relates to methods and compositions comprising marine botanicals for treating aged, mature, nutritionally-compromised, or environmentally-damaged skin. These methods and compositions provide improvements in the skin's visual appearance, physiological functions, clinical properties, and biophysical properties.

Abstract: The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection are further provided. Pharmaceutical, including vaccines, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided.

Abstract: An immunogenic composition and methods for producing said composition, the composition comprising VLPs from HPV 16 and 18 and at least one other HPV cancer type, the other cancer type being selected from the list consisting of HPV types 31, 45 and 52, wherein the dose of the VLP of the at least one other cancer types is reduced relative to that of HPV 16 or 18.

Abstract: The present invention relates to an isolated attenuated influenza virus strain and a live vaccine comprising the same. The isolated attenuated influenza virus strain is prepared by cold-adaptation of a mother strain which carries 6 internal genomes of A/PR/8/34(H1N1) and two surface antigens HA and NA of A/Aichi/2/68(H3N2). The attenuated influenza virus strain and the live vaccine of the present invention are useful for prevention of seasonal influenza episodes and sudden outbreak of influenza pandemics of predicted or unknown identity, since they have safety, efficacy, high production yield, immediate protection against variety of influenza subtypes and prolonged protection against specific influenza subtype.

Abstract: The invention encompasses compositions and methods relating to viral polymerases having one or more substitutions of different amino acids at conserved regions of the polymerase yields enzymes with varying rates and fidelity of replication. A universally applicable, polymerase-mechanism-based strategy for production of attenuated viruses and anti-viral vaccines is disclosed.

Abstract: The invention relates to immunogenic compositions and to methods for immunizing animals using the same. The immunogenic composition comprises a lipid formulation most usually in solid form, and at least one immunogenic component. A preferred immunogenic component is a living organism. In a preferred embodiment the composition is formulated for oral administration.

Abstract: The present invention relates to Lawsonia intracellularis vaccines and methods for protecting against and diagnosing L. intracellularis infection. The products and processes of the invention are attainable, in part, as the result of an improved method for cultivating large scale supplies of L. intracellularis, including both a novel isolate of L. intracellularis of European origin and a method of preparing a lyophilized product containing the attenuated European isolate as vaccine product.

Abstract: Pharmaceutical compositions for transdermal administration of neurotoxins to a patient include a neurotoxin, such as a botulinum toxin, and an enhancing agent that facilitates absorption of the neurotoxin through the skin of the patient and does not eliminate the bioactivity associated with the neurotoxin. The pharmaceutical compositions are topically applied on a patient, and may be provided in a transdermal patch.

Abstract: Methods are disclosed herein for treating depression in the subject. A method includes the use of Botulinum toxin to cause paralysis of a facial muscle, such as the depressor anguli oris, procerus, frontalis, orbicularis oculi, or corrugator supercilii muscle to treat depression in the subject.

Abstract: This invention relates to the use of a composition comprising a polysaccharide and a botulinum toxin for reducing a skin wrinkle. In some embodiments, the polysaccharide comprises disaccharides. In some embodiments, the average molecular weight of a disaccharide unit of the polysaccharide is between about 345 D and about 1,000 D.

Abstract: Non-naturally occurring mycobacteria in the Mycobacterium tuberculosis complex are provided. These mycobacteria have a deletion of an RD1 region or a region controlling production of a vitamin, and exhibit attenuated virulence in a mammal when compared to the mycobacteria without the deletion. Also provided are non-naturally occurring mycobacteria that have a deletion of a region controlling production of lysine, and mycobacteria comprising two attenuating deletions. Vaccines comprising these mycobacteria are also provided, as are methods of protecting mammals from virulent mycobacteria using the vaccines. Also provided are methods of preparing these vaccines which include the step of deleting an RD1 region or a region controlling production of a vitamin or the amino acids leucine and lysine from a mycobacterium in the M. tuberculosis complex. Embodiments of these mycobacteria, vaccines and methods, encompassing mycobacteria comprising a leucine auxotrophy and a pantothenate auxotrophy, are also provided.

Abstract: The invention provides a vaccine comprising secreted protein derived from Mycobacterium avium subsp paratuberculosis (M. ptb) substantially free of whole organisms of that species either dead or alive. The secreted protein may be obtained from a culture of M. ptb with the microorganisms being removed by centrifugation and subsequent filtration. The vaccine may be used for vaccination against Johne's disease.

Abstract: The present disclosure relates to a method of preventing or treating an infection caused by a bioterrorism agent, specifically to a method of increasing an immune response to a bioterrorism agent using an oligodeoxynucleotide including a CpG motif, and a method of enhancing the immunogenicity of a vaccine against a bioterrorism agent using an oligodeoxynucleotide including a CpG motif.

Abstract: The present invention provides for a storage stable pharmaceutical liquid suspension for oral administration having a pharmaceutically effective amount of an antihistamine. The storage stable suspension preferably contains loratadine. The present invention further provides a process of preparing the storage stable pharmaceutical liquid suspension as well as a method of treating a mammal with a therapeutically effective amount of loratadine in the stable pharmaceutical liquid suspension.

Abstract: A cosmetic treatment system is provided having ingredients that may prevent signs of aging, improve the aesthetic appearance of skin, and promote recovery from environmental stresses. The composition includes natural ingredients, including at least one ingredient or extract from rosemary; at least one ingredient or extract from Centella, Echinacea, Alpinia or mixtures thereof; a DNA repair enzyme; and at least one pharmaceutically or cosmetically acceptable vehicle. The treatment system may further include a patch for applying the cosmetic ingredients and/or a packaging system for holding the components of the cosmetic treatment system.

Abstract: The device for dispensing a volatile insecticide or repellent includes a sheet impregnated with an insecticidal/repellent component which volatilizes at an ordinary temperature; a flat box for detachably holding the sheet, the flat box having a sheet-exposing aperture for volatilizing the insecticidal component from the held impregnated sheet; and a suspension cord for three-dimensionally assembling a plurality of the flat box.

Abstract: A composition is disclosed comprising a structural component comprising linear acrylic homopolymers or linear acrylic copolymers and a biobeneficial component comprising copolymers having an acrylate moiety and a biobeneficial moiety.

Abstract: Drug-delivery systems such as drug-delivery stents having an anti-proliferative agent such as everolimus and an anti-inflammatory agent such as clobetasol are provided.

Abstract: Composite biomaterials (e.g., for use as orthopedic implants), as well as methods of preparing composite biomaterials, are disclosed. The composite biomaterial includes a matrix (e.g., a continuous phase) comprising a thermoplastic, a calcium phosphate composition that is curable in vivo, or combinations thereof. The composite biomaterial also includes an isometric calcium phosphate reinforcement particles which are dispersed within the matrix.

Abstract: An artificial tear film over the surface of an eye having a first layer in direct contact with the ocular surface, an aqueous layer over the first layer, and a layer of a phospholipid over the aqueous layer. The first layer has polyvinyl alcohol, polyvinyl acetate, and polyvinyl pyrrolidone. The phospholipid is derived from Amisol® Clear. The artificial tear film is effective in significantly prolonging the tear break up time in patients with dry eye syndrome.

Abstract: The absorption and deposition of carotenoids added to poultry diets into the yolk of eggs produced by the poultry is improved by adding a carotenoid formulation comprising a carotenoid, a vegetable oil, a surfactant, a chelating agent, an antioxidant, an alkali and a solvent. The carotenoid formulation can reduce the crystalline nature of lutein for its better dissolution in the formulation and the diet. This new formulation is capable of making more micelles for an effective transfer of lutein from the formulations to the aqueous layer. The new formulation can increase the bioavailability of lutein in chicken biological system and leads to more deposition in the blood and the egg. The lutein deposition in the egg was consistent for an extended period of time when this new formulation was added to the diet. Addition of this carotenoid formulation to the diet increased the antioxidant power of the blood. Eggs produced by poultry fed diets supplemented by the formulation have in excess of 0.

Abstract: The invention relates to a soothing lotion, which cleanses, moisturizes and protects the skin and controls odor from feces and urine on skin. The invention also relates to a cloth comprising said lotion.

Abstract: Sterile compositions for administration as aerosols are described. They contain an active agent which is poorly water-soluble, a non-ionic surfactant acomponent and a phospholipid component. The compositions are suitable for oral or nasal inhalation, but also for topical or oromucosal administration. They are particulary useful for the efficient pulmonary administration of poorly soluble corticosteroids and can be aerosolized with common nebulizers.

Abstract: This invention relates to substantially anhydrous warming, non-toxic and nonirritating lubricating compositions containing polyhydric alcohols and an insulating agent as well as gel and jelly compositions related thereto. The invention also relates to methods of using such compositions for lubrication, administration of active ingredients and for preventing or treating dysmenorrhea.

Abstract: A therapeutic, cosmetic or cosmeceutic composition for topical application, capable of stabilizing an active ingredient and delivering the active ingredient, comprising a plurality of microcapsules having a core-shell structure. The microcapsules have a diameter of approximately 0.1 to 100 micron. The core of each microcapsule includes at least one active ingredient and is encapsulated within a microcapsular shell. The shell is comprised of at least one inorganic polymer obtained by a sol-gel process, and the shell protects the active ingredient before topical application and is designed to release the active ingredient from the microcapsules following application. The composition is useful in encapsulating active ingredients, such as benzoyl peroxide, that are unstable in other formulation, or are irritating to the skin.

Abstract: Herein we disclose a composition, comprising a Cn-Ab, wherein Cn is a fullerene or nanotube comprising n carbon atoms, and Ab is a moiety comprising an antigen-binding site and is linked to the Cn. The composition can further comprise a therapeutic molecule associated with the Cn-Ab. Also, we disclose a method of treating a disease in a mammal, comprising administering to the mammal an effective amount of the composition.

Abstract: Low volume safe for injection formulations of dantrolene yield significant advantages over the currently approved and marketed dantrolene for MH threatening anesthetic crisis. Once dantrolene can be made immediately available to patients triggered of MH, the anesthesiologist will be able to focus exclusively on the management of the patient's physiologic status in this complex and evolving crisis, not on the laborious and time consuming reconstitution process of the rescue agent. Additionally, a safe for injection low volume formulation of dantrolene can be made widely available to non-anesthesiologist practitioners who have occasion to use dantrolene intravenously in the treatment of other potentially life threatening conditions, including in the field.

Abstract: The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents, or combinations thereof. Also provided are methods of administering to an individual a drug taxane in a nanoparticle composition based on a metronomic dosing regime.